Processing

Please wait...

Settings

Settings

Goto Application

1. WO2023283684 - COMPOSITION COMPRISING CANNABIDIOL AND HYDROXYCHLOROQUINE IN A FIXED DOSE COMBINATION CAPSULE

Publication Number WO/2023/283684
Publication Date 19.01.2023
International Application No. PCT/AU2022/050731
International Filing Date 13.07.2022
IPC
A61P 29/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (NSAIDs)
A61K 36/185 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
36Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
18Magnoliophyta (angiosperms)
185Magnoliopsida (dicotyledons)
A61K 31/05 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
05Phenols
A61K 31/4706 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
47064-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
A61K 47/10 2017.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
08containing oxygen
10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols ; Poloxamers; PEG/POE alkyl ethers
A61K 47/44 2017.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42107; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Applicants
  • INCANNEX HEALTHCARE LIMITED [AU]/[AU]
Inventors
  • BLEACKLEY, Mark Robert
  • LATHAM, Joel Bradley
Agents
  • DAVIES COLLISON CAVE PTY LTD
Priority Data
202190217015.07.2021AU
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) COMPOSITION COMPRISING CANNABIDIOL AND HYDROXYCHLOROQUINE IN A FIXED DOSE COMBINATION CAPSULE
(FR) COMPOSITION COMPRENANT DU CANNABIDIOL ET DE L'HYDROXYCHLOROQUINE DANS UNE CAPSULE COMBINÉE À DOSE FIXE
Abstract
(EN) The present disclosure relates generally to compositions comprising a synergistic combination of cannabidiol (CBD) or a pharmaceutically acceptable salt or derivative thereof and hydroxychloroquine or a pharmaceutically acceptable salt thereof, which beneficially enables simultaneous administration of the two active pharmaceutical ingredients (APIs) in a single dosage form. In an embodiment, the present disclosure also relates to methods and uses of the composition for the treatment of an inflammatory condition.
(FR) La présente invention concerne de manière générale des compositions comprenant une combinaison synergique de cannabidiol (CBD) ou un sel pharmaceutiquement acceptable ou un dérivé de celui-ci et de l'hydroxychloroquine ou un sel pharmaceutiquement acceptable de celui-ci, qui permet avantageusement l'administration simultanée des deux ingrédients pharmaceutiques actifs (API) sous une forme posologique unique. Dans un mode de réalisation, la présente invention concerne également des procédés et des utilisations de la composition pour le traitement d'une affection inflammatoire.
Latest bibliographic data on file with the International Bureau